According to a study by Stewart et al., a methylation status analysis in 14 paired RCC specimens (before and after treatment with sunitinib) showed that the VHL promoter region 7896829 was significantly more methylated after sunitinib (14% of patients with hypermethylation before treatment, 64% post-treatment, p < 0.001, False Discovery Rate, FDR = 0.077) [26]. The gene discussed is VHL; the disease is renal cell adenocarcinoma.